Lauren Averett Byers

6767 Bertner Ave, Mitchell Basic Science Research Building
77030 Houston
United States

h-index

Research activity per year

Fingerprint

Dive into the research topics where Lauren Averett Byers is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

154 Article
19 Review article
9 Comment/debate
4 Chapter
More

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets
Zhang, B., Lewis, W., Stewart, C. A., Morris, B. B., Solis, L. M., Serrano, A., Xi, Y., Wang, Q., Lopez, E. R., Concannon, K., Heeke, S., Tang, X., Raso, G., Cardnell, R. J., Vokes, N., Blumenschein, G., Elamin, Y., Fosella, F., Tsao, A. & Skoulidis, F. & 16 others, Hume, C. B., Sasak, K., Lewis, J., Rinsurongkawong, W., Rinsurongkawong, V., Lee, J., Tran, H., Zhang, J., Gibbons, D., Vaporciyan, A., Wang, J., Park, K., Heymach, J. V., Byers, L. A., Gay, C. M. & Le, X., Feb 2024, In: JTO Clinical and Research Reports. 5, 2, 100623.
Research output: Contribution to journal › Article › peer-review

Open Access
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Zhou, D., Byers, L. A., Sable, B., Smit, M. A. D., Sadraei, N. H., Dutta, S. & Upreti, V. V., Mar 2024, In: Journal of Clinical Pharmacology. 64, 3, p. 362-370 9 p.
Research output: Contribution to journal › Article › peer-review
12 Scopus citations
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer
Park, S., Hong, T. H., Hwang, S., Heeke, S., Gay, C. M., Kim, J., Jung, H. A., Sun, J. M., Ahn, J. S., Ahn, M. J., Cho, J. H., Choi, Y. S., Kim, J., Shim, Y. M., Kim, H. K., Byers, L. A., Heymach, J. V., Choi, Y. L., Lee, S. H. & Park, K., Apr 2024, In: EBioMedicine. 102, 105062.
Research output: Contribution to journal › Article › peer-review

Open Access
7 Scopus citations
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., Juan, J. M., Min, C., Yu, Y., Pan, X., Arbour, K. C., Vokes, N., Schmidt, S. T., Molkentine, D., Owen, D. H. & Memmott, R. & 111 others, Patil, P. D., Marmarelis, M. E., Awad, M. M., Murray, J. C., Hellyer, J. A., Gainor, J. F., Dimou, A., Bestvina, C. M., Shu, C. A., Riess, J. W., Blakely, C. M., Pecot, C. V., Mezquita, L., Tabbó, F., Scheffler, M., Digumarthy, S., Mooradian, M. J., Sacher, A. G., Lau, S. C. M., Saltos, A. N., Rotow, J., Johnson, R. P., Liu, C., Stewart, T., Goldberg, S. B., Killam, J., Walther, Z., Schalper, K., Davies, K. D., Woodcock, M. G., Anagnostou, V., Marrone, K. A., Forde, P. M., Ricciuti, B., Venkatraman, D., Van Allen, E. M., Cummings, A. L., Goldman, J. W., Shaish, H., Kier, M., Katz, S., Aggarwal, C., Ni, Y., Azok, J. T., Segal, J., Ritterhouse, L., Neal, J. W., Lacroix, L., Elamin, Y. Y., Negrao, M. V., Le, X., Lam, V. K., Lewis, W. E., Kemp, H. N., Carter, B., Roth, J. A., Swisher, S., Lee, R., Zhou, T., Poteete, A., Kong, Y., Takehara, T., Paula, A. G., Parra Cuentas, E. R., Behrens, C., Wistuba, I. I., Zhang, J., Blumenschein, G. R., Gay, C., Byers, L. A., Gibbons, D. L., Tsao, A., Lee, J. J., Bivona, T. G., Camidge, D. R., Gray, J. E., Lieghl, N., Levy, B., Brahmer, J. R., Garassino, M. C., Gandara, D. R., Garon, E. B., Rizvi, N. A., Scagliotti, G. V., Wolf, J., Planchard, D., Besse, B., Herbst, R. S., Wakelee, H. A., Pennell, N. A., Shaw, A. T., Jänne, P. A., Carbone, D. P., Hellmann, M. D., Rudin, C. M., Albacker, L., Mann, H., Zhu, Z., Lai, Z., Stewart, R., Peters, S., Johnson, M. L., Wong, K. K., Huang, A., Winslow, M. M., Rosen, M. J., Winters, I. P., Papadimitrakopoulou, V. A., Cascone, T., Jewsbury, P. & Heymach, J. V., Nov 14 2024, In: Nature. 635, 8038, p. 462-471 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
6 Scopus citations
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
Serrano, A. G., Rocha, P., Freitas Lima, C., Stewart, A., Zhang, B., Diao, L., Fujimoto, J., Cardnell, R. J., Lu, W., Khan, K., Sable, B., Ellison, A. R., Wistuba, I. I., Concannon, K. F., Halperin, D. M., Bogdan, C., Sircar, K., Zhang, M., Cargill, K. & Wang, Q. & 10 others, Aparicio, A., Lazar, A., Hernandez, S., Estrella, J., Ramalingam, P., El-Naggar, A., Kalhor, N., Gay, C. M., Byers, L. A. & Solis Soto, L. M., Dec 2024, In: npj Precision Oncology. 8, 1, 268.
Research output: Contribution to journal › Article › peer-review

Open Access

Lauren Averett Byers

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms

Lauren Averett Byers

Fingerprint

Collaborations and top research areas from the last five years

Research output

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms